All Five Agenda Items, Including Amendments to Articles of Incorporation, Approved as Originally Proposed

Samsung Biologics held its 15th Annual General Meeting of Shareholders on the 20th at Incheon Songdo Convensia.


At the meeting, five agenda items were proposed: approval of the financial statements, amendments to the articles of incorporation, appointment of inside directors, appointment of audit committee members and outside directors, and approval of the limit on directors’ remuneration. All five items were approved as originally proposed.


In his welcoming remarks, CEO John Lim stated, "Last year, through a spin-off, we became a pure CDMO (Contract Development and Manufacturing Organization), resolving concerns over conflicts of interest among our clients. We also secured a global production base by deciding to acquire the Rockville facility in the United States." He added, "We have focused on expanding our portfolio, including the launch of organoid services and securing land for the third Bio Campus to respond to new modalities (therapeutic approaches)."

John Rim, CEO of Samsung Biologics, is speaking at the 15th Annual General Meeting held at Songdo Convensia in Incheon on the 20th.

John Rim, CEO of Samsung Biologics, is speaking at the 15th Annual General Meeting held at Songdo Convensia in Incheon on the 20th.

View original image

This year’s meeting was conducted both in person and via live online broadcast, with approximately 1,400 shareholders participating. To enhance shareholder convenience, the company supported the exercise of voting rights by conducting electronic voting for ten days from the 10th to the 19th.


CEO John Lim and Gyun Roh, Head of EPCV Center, were reappointed as inside directors. Jungyeon Kim, a professor at Ewha Womans University Law School, was newly appointed as an outside director and audit committee member.



CEO John Lim said, "We will successfully complete the acquisition of the U.S. facility and quickly establish it as a core base for global production. We will also proceed without delay in constructing our second and third Bio Campuses in Korea." He added, "Beyond CMO (Contract Manufacturing Organization) services, we will further strengthen our CDO (Contract Development Organization) competitiveness, as well as our capabilities in antibody-drug conjugates (ADC), organoids, and more, to become an end-to-end partner that satisfies global clients."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing